Scpharmaceuticals (SCPH) Downgraded by Zacks Investment Research to Sell

Zacks Investment Research lowered shares of Scpharmaceuticals (NASDAQ:SCPH) from a hold rating to a sell rating in a research note issued to investors on Wednesday morning.

According to Zacks, “scPharmaceuticals, Inc., is a biopharmaceutical company. It engaged in developing pharmaceutical products for subcutaneous delivery. The Company’s pipeline programs include: scFurosemide lead product candidate, Furoscix, consists of its proprietary subcutaneous formulation of furosemide delivered via sc2Wear Infusor for diuresis in heart failure patients outside of the acute care setting. scPharmaceuticals, Inc., is based in BURLINGTON, United States. “

Several other analysts have also weighed in on SCPH. BMO Capital Markets started coverage on Scpharmaceuticals in a report on Tuesday, December 12th. They issued an outperform rating and a $24.00 price objective for the company. Leerink Swann started coverage on Scpharmaceuticals in a report on Tuesday, December 12th. They issued an outperform rating and a $20.00 price objective for the company. Finally, Jefferies Group started coverage on Scpharmaceuticals in a report on Tuesday, December 12th. They issued a buy rating and a $23.00 price objective for the company.

Shares of Scpharmaceuticals (NASDAQ:SCPH) opened at $13.39 on Wednesday. Scpharmaceuticals has a fifty-two week low of $11.50 and a fifty-two week high of $18.17.

In other news, major shareholder 5Am Partners Iv, Llc acquired 654,762 shares of the stock in a transaction that occurred on Tuesday, November 21st. The stock was purchased at an average cost of $14.00 per share, with a total value of $9,166,668.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

A number of institutional investors have recently made changes to their positions in SCPH. Bank of New York Mellon Corp bought a new stake in Scpharmaceuticals in the fourth quarter valued at about $414,000. Monashee Investment Management LLC bought a new position in shares of Scpharmaceuticals during the fourth quarter valued at approximately $230,000. AWM Investment Company Inc. bought a new position in shares of Scpharmaceuticals during the fourth quarter valued at approximately $1,996,000. Nicholas Investment Partners LP bought a new position in shares of Scpharmaceuticals during the fourth quarter valued at approximately $1,500,000. Finally, Goldman Sachs Group Inc. bought a new position in shares of Scpharmaceuticals during the fourth quarter valued at approximately $653,000. 0.07% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Scpharmaceuticals (SCPH) Downgraded by Zacks Investment Research to Sell” was originally published by Markets Daily and is the sole property of of Markets Daily. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.themarketsdaily.com/2018/02/15/scpharmaceuticals-scph-downgraded-by-zacks-investment-research-to-sell.html.

Scpharmaceuticals Company Profile

scPharmaceuticals, Inc, is a biopharmaceutical company. The Company is engaged in developing pharmaceutical products for subcutaneous delivery. The Company offers sc2Wear Infusor, which is a small pump that attaches to the body using a standard medical adhesive. The sc2Wear Infusor injects the drug into the body slowly, similar to an intravenous (IV) drip.

Get a free copy of the Zacks research report on Scpharmaceuticals (SCPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply